1. A topical pharmaceutical composition comprising 2,3-dimethyl-6- (N, N-dimethylaminoethyl) -6H-indolo- (2,3-b) quinoxaline (B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable media. 2. The pharmaceutical composition according to claim 1, containing B-220 in an amount of 0.1-10% (weight / weight). The pharmaceutical composition according to claim 1, containing B-220 in an amount of 0.5-5% (weight / weight). The pharmaceutical composition according to claim 1, containing at least one additional therapeutically active ingredient. The pharmaceutical composition according to claim 4, wherein the additional therapeutically active ingredient is selected from antiviral agents, antibiotics, analgesics, anesthetics, antiphlogistic agents, and anti-inflammatory agents. The pharmaceutical composition of claim 5, wherein the additional therapeutically active ingredient is an antiphlogistone agent. The pharmaceutical composition of claim 5, wherein the additional therapeutically active ingredient is an anti-inflammatory agent. The pharmaceutical composition according to claim 4, wherein the additional therapeutically active ingredient is present in an amount of 0.005-5% (weight / weight). The pharmaceutical composition according to claim 2, containing at least one additional therapeutically active ingredient. The pharmaceutical composition according to claim 9, wherein the additional therapeutically active ingredient is selected from antiviral agents, antibiotics, analgesics, anesthetics, antiphlogistic agents, and anti-inflammatory drugs. The pharmaceutical composition of claim 9, wherein the additional therapeutically active ingredient is present in an amount of 01. Фармацевтическая композиция для местного применения, содержащая 2,3-диметил-6-(N,N-диметиламиноэтил)-6Н-индоло-(2,3-b)хиноксалин (В-220) или его фармацевтически приемлемую соль в фармацевтически приемлемом носителе.2. Фармацевтическая композиция по п.1, содержащая В-220 в количес
